Related references
Note: Only part of the references are listed.Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias
Omar Abdel-Wahab et al.
CANCER RESEARCH (2010)
Somatic Mutations of IDH1 and IDH2 in the Leukemic Transformation of Myeloproliferative Neoplasms
Anthony Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Omar Abdel-Wahab et al.
BLOOD (2009)
In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm
Jonathan R. Lambert et al.
BLOOD (2009)
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
Paola Guglielmelli et al.
BLOOD (2009)
Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells
Toshihiko Tanno et al.
BLOOD (2009)
Mutations in CBL occur frequently in juvenile myelomonocytic leukemia
Mignon L. Loh et al.
BLOOD (2009)
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms
Anna M. Jankowska et al.
BLOOD (2009)
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
Francis H. Grand et al.
BLOOD (2009)
Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies
Hideki Makishima et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Novel TET2 Mutations Associated With UPD4q24 in Myelodysplastic Syndrome
Azim M. Mohamedali et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
A. Tefferi et al.
LEUKEMIA (2009)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi et al.
LEUKEMIA (2009)
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML
A. Tefferi et al.
LEUKEMIA (2009)
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
Masashi Sanada et al.
NATURE (2009)
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
Damla Olcaydu et al.
NATURE GENETICS (2009)
A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
Outi Kilpivaara et al.
NATURE GENETICS (2009)
Acquired mutations in TET2 are common in myelodysplastic syndromes
Saskia M. C. Langemeijer et al.
NATURE GENETICS (2009)
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
Amy V. Jones et al.
NATURE GENETICS (2009)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Mamta Tahiliani et al.
SCIENCE (2009)
The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity
Chloe James et al.
BLOOD (2008)
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice
Shu Xing et al.
BLOOD (2008)
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Ralph Tiedt et al.
BLOOD (2008)
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
Isabelle Plo et al.
BLOOD (2008)
Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells
Clotilde Simon et al.
BLOOD (2008)
Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders
Daniela Capello et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
250K Single Nucleotide Polymorphism Array Karyotyping Identifies Acquired Uniparental Disomy and Homozygous Mutations, Including Novel Missense Substitutions of c-Cbl, in Myeloid Malignancies
Andrew J. Dunbar et al.
CANCER RESEARCH (2008)
Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases
Luciana Teofili et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
SOCS2: inhibitor of JAK2V617F-mediated signal transduction
H. Quentmeier et al.
LEUKEMIA (2008)
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
A. Tefferi et al.
LEUKEMIA (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
JAK and MPL mutations in myeloid malignancies
Ayalew Tefferi
LEUKEMIA & LYMPHOMA (2008)
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Charles G. Mullighan et al.
NATURE (2008)
Inhibition of the Bcl-xL Deamidation Pathway in Myeloproliferative Disorders
Rui Zhao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
SOCS regulation of the JAK/STAT signalling pathway
Ben A. Croker et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
Animesh Pardanani et al.
BLOOD (2008)
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
Daniela Pietra et al.
BLOOD (2008)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F
K. Shide et al.
LEUKEMIA (2008)
JAK2 Mutations are present in all cases of polycythemia vera
Y. L. Wang et al.
LEUKEMIA (2008)
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia
Elisabetta Antonioli et al.
HAEMATOLOGICA (2007)
Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders
Sigal Gery et al.
BLOOD (2007)
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera
A. Pardanani et al.
LEUKEMIA (2007)
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
A. M. Vannucchi et al.
LEUKEMIA (2007)
Flt3-dependent transformation by inactivating c-Cbl mutations in AML
Buelent Sargin et al.
BLOOD (2007)
The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera
Sabrina Dupont et al.
BLOOD (2007)
Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia
Michael A. Caligiuri et al.
BLOOD (2007)
Leukemic blasts in transfon-ned JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
Alexandre Theocharides et al.
BLOOD (2007)
Clinical correlates of JAK2V617F allele burden in essential thrombocythemia
Jaya Kittur et al.
CANCER (2007)
The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3
Michelle B. Hookham et al.
BLOOD (2007)
The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders
Thomas Stauffer Larsen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Jak2: normal function and role in hematopoietic disorders
James N. Ihle et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
DNA damage-induced Bcl-x(L) deamidation is mediated by NHE-1 antiport regulated intracellular pH
Rui Zhao et al.
PLOS BIOLOGY (2007)
Oncogenes in myeloproliferative disorders
Ayalew Tefferi et al.
CELL CYCLE (2007)
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
E. Jost et al.
LEUKEMIA (2007)
Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera
A. Tefferi et al.
LEUKEMIA (2007)
Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease
Lynda A. O'Sullivan et al.
MOLECULAR IMMUNOLOGY (2007)
Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis
Francois Delhommeau et al.
BLOOD (2007)
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Ross L. Levine et al.
NATURE REVIEWS CANCER (2007)
Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
Virginia M. Zaleskas et al.
PLOS ONE (2006)
Characterization of murine JAK2V617F-positive myeloproliferative disease
Thomas G. P. Bumm et al.
CANCER RESEARCH (2006)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Peter J. Campbell et al.
BLOOD (2006)
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera
Takefumi Ishii et al.
BLOOD (2006)
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
Linda M. Scott et al.
BLOOD (2006)
Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK
Natalija Buza-Vidas et al.
GENES & DEVELOPMENT (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Gerlinde Wernig et al.
BLOOD (2006)
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation
CHM Jamieson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
JAW/STAT signal transduction: Regulators and implication in hematological malignancies
L Valentino et al.
BIOCHEMICAL PHARMACOLOGY (2006)
V617F mutation in JAK2 is associated idiopathic myelofibrosis
PJ Campbell et al.
BLOOD (2006)
JAK2(V617F) expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
Catherine Lacout et al.
BLOOD (2006)
The Cbl interactome and its functions
MHH Schmidt et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia:: lineage specificity and clinical correlates
A Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Common 4q24 deletion in four cases of hematopoietic malignancy:: early stem cell involvement?
F Viguié et al.
LEUKEMIA (2005)
Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways
W Tong et al.
BLOOD (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera
V Ugo et al.
EXPERIMENTAL HEMATOLOGY (2004)
Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis
W Tong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
CHM Jamieson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation
S Haan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: Possible relationship with FKBP51 overexpression
E Komura et al.
EXPERIMENTAL HEMATOLOGY (2003)
TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23)
RB Lorsbach et al.
LEUKEMIA (2003)
Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice
L Velazquez et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1
D Ungureanu et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor
M Hörtner et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2002)
Signaling through the JAK/STAT pathway, recent advances and future challenges
T Kisseleva et al.
GENE (2002)
Enhanced Hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk
S Takaki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera
R Kralovics et al.
EXPERIMENTAL HEMATOLOGY (2002)
STAT3 is constitutively active in some patients with Polycythemia rubra vera
S Röder et al.
EXPERIMENTAL HEMATOLOGY (2001)
Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation
J Frantsve et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Control of B cell production by the adaptor protein Lnk: Definition of a conserved family of signal-modulating proteins
S Takaki et al.
IMMUNITY (2000)
Share Paper
